File No. CT/114/23-DCG(I)

GOVERNMENT OF INDIA
CENTRAL DRUGS STANDARD CONTROL ORGANISATION(Headquarter)(Directorate General ofHealthServices) Ministry of Health & Family Welfare
FDA Bhavan
ITO, KotlaRoad New Delhi - 110002 (Delhi) Phone No.:91-11-23216367
Fax No.: 91-11-23236973
E-Mail : dci@nic.in

सत्यमेव जयते

File No. CT/23/000114

To,

M/s. AstraZeneca Pharma India Limited,
Block NO 1, 12th Floor Manyata Embassy,
Business Park, Rachenahalli Outer Ring Road,
Bangalore, Karnataka (India) – 560045.

Sir,

With reference to your application No. GCT/CT04/FF/2023/39566 (GCT/114/23) dated 13-09-2023, please find enclosed herewith the permission in Form CT-06 for conduct of phase III clinical trial titled, **"A Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of Baxdrostat in Participants with Uncontrolled Hypertension on Two or More Medications including Participants with Resistant Hypertension" Protocol No: D6970C00002, Version 1.0, dated 14/Jul/2023 with a total of up-to 55 subjects from India** under the provisions of New Drugs and Clinical Trial Rules, 2019

The permission granted by the Central Licensing Authority to conduct clinical trial shall be subject to following conditions, namely:-

(i) Atleast 50% trial sites should be govt. sites & Atleast 50% subjects shall be enrolled from govt. sites;
(ii) Investigators in the study should be Cardiologists only;
(iii) Co-medication & Other treatment including follow up should be borne by the sponsor;
(iv) Clinical trial at each site shall be initiated after approval of the clinical trial protocol and other related documents by the Ethics Committee of that site, registered with the Central Licencing Authority under rule 8;
(v) where a clinical trial site does not have its own Ethics Committee, clinical trial at that site may be initiated after obtaining approval of the protocol from the Ethics Committee of another trial site; or an independent Ethics Committee for clinical trial constituted in accordance with the provisions of rule 7:
Provided that the approving Ethics Committee for clinical trial shall in such case be responsible for the study at the trial site or the centre, as the case may be:
Provided further that the approving Ethics Committee and the clinical trial site or the bioavailability and bioequivalence centre, as the case may be, shall be located within the same city or within a radius of 50 kms of the clinical trial site;

(vi) in case an ethics committee of a clinical trial site rejects the approval of the protocol, the details of the same shall be submitted to the Central Licensing Authority prior to seeking approval of another Ethics Committee for the protocol for conduct of the clinical trial at the same site;

(vii) the Central Licencing Authority shall be informed about the approval granted by the Ethics Committee within a period of fifteen working days of the grant of such approval;

(viii) clinical trial shall be registered with the Clinical Trial Registry of India maintained by the Indian Council of Medical Research before enrolling the first subject for the trial;

(ix) clinical trial shall be conducted in accordance with the approved clinical trial protocol and other related documents and as per requirements of Good Clinical Practices Guidelines and the provisions of these rules;

(x) status of enrolment of the trial subjects shall be submitted to the Central Licencing Authority on quarterly basis or as appropriate as per the duration of treatment in accordance with the approved clinical trial protocol, whichever is earlier;

(xi) six monthly status report of each clinical trial, as to whether it is ongoing, completed or terminated, shall be submitted to the Central Licencing Authority electronically in the SUGAM portal;

(xii) in case of termination of any clinical trial the detailed reasons for such termination shall be communicated to the Central Licencing Authority within thirty working days of such termination;

(xiii) any report of serious adverse event occurring during clinical trial to a subject of clinical trial, shall, after due analysis, be forwarded to the Central Licencing Authority, the chairperson of the Ethics Committee and the institute where the trial has been conducted within fourteen days of its occurrence as per Table 5 of the Third Schedule and in compliance with the procedures as specified in Chapter VI;

(xiv) in case of injury during clinical trial to the subject of such trial, complete medical management and compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of the receipt of order issued by Central Licencing Authority in accordance with the provisions of the said Chapter;

(xv) in case of clinical trial related death or permanent disability of any subject of such trial during the trial, compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of receipt of the order issued by the Central Licencing Authority in accordance with the provisions of the said Chapter;

(xvi) the premises of the sponsor including his representatives and clinical trial sites, shall be open for inspection by officers of the Central Licencing Authority who may be accompanied by officers of the State Licencing Authority or outside experts as authorised by the Central Licencing Authority, to verify compliance of the requirements of these rules and Good Clinical Practices Guidelines, to inspect, search and seize any record, result, document, investigational product, related to clinical trial and furnish reply to query raised by the said officer in relation to clinical trial;

(xvii) where the new drug or investigational new drug is found to be useful in clinical development, the sponsor shall submit an application to the Central Licencing Authority for permission to import or manufacture for sale or for distribution of new drug in India, in accordance with Chapter X of these rules, unless otherwise justified;

(xviii) the laboratory owned by any person or a company or any other legal entity and utilised by that person to whom permission for clinical trial has been granted used for research and development, shall be deemed to be registered with the Central Licensing Authority and may be used for test or analysis of any drug for and on behalf of Central Licensing Authority;

(xix) the Central Licencing Authority may, if considered necessary, impose any other condition in writing with justification, in respect of specific clinical trials, regarding the objective, design, subject population, subject eligibility, assessment, conduct and treatment of such specific clinical trial;

(xx) the sponsor and the investigator shall maintain the data integrity of the data generated during clinical trial.

(xxi) Merely granting permission to conduct the clinical trial with the Investigational Drug Product does not convey or imply that, based on the clinical trial study datagenerated with the investigational drug, permission to market this drug in the country will automatically be granted to you;

(xxii) The permission to initiate clinical trial granted under rule 22 in form CT-06 or automatic approval under rule 23 in Form CT 4A shall remain valid for a period of **two years** from the date of its issue, unless extended by the Central Licencing Authority.

Yours faithfully,

RAJEEV SINGH RAGHUVANSHI

Digitally signed by RAJEEV SINGH RAGHUVANSHI
DN: c=IN, o=CENTRAL DRUGS STANDARD CONTROL ORGANIZATION, ou=RAJEEV SINGH RAGHUVANSHI, 2.5.4.20=80c62f6a23e4eafbe8a239774cdeb03c276904 1015a06564fe67f54b765db1cb, postalCode=600034, st=TAMIL NADU, [illegible]
Reason: I am the author of this document
Location: CDSCO
Date: 2024.04.04 16:39:30 IST

(Dr. Rajeev Singh Raghuvanshi)
Drugs Controller General (India)&
Central Licencing Authority
Stamp

File No. CT/114/23-DCG(I)

FORM CT-06

(See rules 22,25,26,29 and 30)

PERMISSION TO CONDUCT CLINICAL TRIAL OF NEW DRUG OR INVESTIGATIONAL NEW DRUG

1. The Central Licensing Authority hereby permits **M/s. AstraZeneca Pharma India Limited, Block NO 1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Bangalore (India) - 560045** to conduct clinical trial of the new drug or investigational new drug as per **Protocol No: D6970C00002, Version 1.0, dated 14/Jul/2023** in the below mentioned clinical trial sites [As per Annexure].-

2. Details of new drug or investigational new drug and clinical trial site [As per Annexure].

3. This permission is subject to the conditions prescribed in part A of Chapter V of the New Drugs and Clinical Trials Rules, 2019 under the Drugs and Cosmetics Act, 1940.

Place: New Delhi
Date _____

RAJEEV SINGH RAGHUVANSHI

Digitally signed by RAJEEV SINGH RAGHUVANSHI
DN: c=IN, o=CENTRAL DRUGS STANDARD CONTROL ORGANIZATION, ou=RAJEEV SINGH RAGHUVANSHI, 2.5.4.20=80c62f6a23e4eafbe8a239774cdeb03c27690410 15a06564fe67f54b765db1cb, postalCode=600034, st=TAMIL NADU, serialNumber=657F5E47D94098SD8F03BDC902D0E1FE7 [illegible]
Date: 2023.12.08 18:51:44 +05'30'

(Dr. Rajeev Singh Raghuvanshi)
Drugs Controller General (India)&
Central Licencing Authority
Stamp

Note: The permission to initiate clinical trial granted under rule 22 in form CT-06 shall remain valid for a period of **two years** from the date of its issue, unless extended by the Central Licencing Authority.

Annexure:
Details of new drug or investigational new drug:

Names of the new drug or investigational new drug	Baxdrostat Tablets 1mg/ Placebo Baxdrostat Tablets 2mg/ Placebo
Therapeutic class:	Selective aldosterone synthase inhibitor
Dosage form:	Tablets
Composition:	Baxdrostat =1.0000 milligram (mg) In House Specification Active Microcrystalline cellulose= 42.7000milligram(mg) U.S.P.,J.P., Ph. Eur Inactive Lactose anhydrous= 30.7000 milligram(mg)U.S.P. Inactive Croscarmellose sodium= 4.0000 milligram(mg)U.S.P., Ph. Eur Inactive Colloidal silicon dioxide= 0.8000 milligram(mg) U.S.P.,J.P., Ph. Eur Inactive Magnesium stearate= 0.8000 milligram(mg) U.S.P.,J.P., Ph. Eur Inactive

	Baxdrostat= 2.0000 milligram (mg)InHouse Specification Active Microcrystalline cellulose= 42.7000milligram(mg) U.S.P.,J.P., Ph. Eur Inactive Lactose anhydrous= 29.7000 milligram (mg) U.S.P., Inactive Croscarmellose sodium= 4.0000milligram(mg) U.S.P.,J.P., Ph. Eur Inactive Colloidal silicon dioxide= 0.8000 milligram (mg) U.S.P.,J.P., Ph. Eur Inactive Magnesium stearate= 0.8000 milligram(mg) U.S.P.,J.P., Ph. Eur Inactive
Indications:	Patients with Uncontrolled Hypertension on Two or More Medications including Participants with Resistant Hypertension

Annexure:

Details of clinical trial site:

Sr. No.	Names and address of clinical trial site	Ethics committee details	Name of investigator
1.	Manipal Hospital, No.85-86, Mysuru-Bengaluru Ring Road Junction, Bannimantap 'A' layout, Siddiqui Nagar, Mysuru, 570015, Karnataka	Institutional Ethics Committee Columbia Asia Hospital Mysore, No. 85-86, Bangalore-Mysore Ring Road Junction, Bannimantapa A Layout, Mandi Mohalla Mysuru, Mysuru (Mysore) Karnataka - 570015 India ECR/1106/Inst/KA/2018/RR-21	Dr. Keshavamurthy C B
2.	VMMC and Safdarjung Hospital, New Delhi-110029	Institutional Ethics Committee, VMMC & Safdarjung Hospital, Room No. 505 & 506, 5th floor. Old OPD Building, VMMC & Safdarjung Hospital, New Delhi-110029. ECR/593/Inst/DL/2014/RR-20	Dr. Sandeep Bansal
3.	IPGME & R and SSKM Hospital, 244, AJC Bose Road, Kolkata-700020, West Bengal, India	IPGME&R Research Oversight Committee 244, AJC Bose Road, Kolkata, West Bengal - 700020, India ECR/35/Inst/WB/2013/RR-19	Dr. Sankar Chandra Mandal
4.	Sir Ganga Ram Hospital, SGRH Marg, Rajinder Nagar, New Delhi-110060, India.	Sir Ganga Ram Hospital Ethics Committee, Room No 1643, 6th floor, Casualty Building, Old Rajinder Nagar, New Delhi-110060 ECR/20/Inst/DL/2013/RR-2019	Dr. J. P. S. Sawhney

File No. CT/114/23-DCG(I)

5.	Nil Ratan Sircar Medical College and Hospital 138, Acharya Jagadish Chandra Bose Road, Sealdah, Kolkata-700014, West Bengal, India.	Ethics Committee NRS Medical College, 138, AJC Bose Road, Kolkata- 700014, West Bengal, India. ECR/609/Inst/WB/2014/RR-20	Dr Swapan Kumar Halder
6.	Max Super Specialty Hospital, (East Block) (A Unit of Devki Devi Foundation), 2, Press Enclave Road, Saket, New Delhi -110017	Institutional Ethics Committee Service Floor, Office of Ethics Committee, East Block, Next to Conference Room, Max Super Specialty Hospital Saket (East Block) (A unit of Devki Devi Foundation) 2, Press Enclave Road, New Delhi- 110017, India ECR/110/Inst/DL/2013/RR- 19	Dr. V K Chopra
7.	Room no-133, First Floor, Academic Block, Department of Cardiology, G.B. Pant Institute of Postgraduate Medical Education & Research, Jawahar Lal Nehru Marg, New Delhi-110002, India	Institutional Ethics Committee, Room No. 306-A, Maulana Azad Medical College, New Delhi -110002. ECR/329/Inst/DL/2013/RR- 19	Dr. Vimal Mehta
8.	LPS institute of Cardiology & Cardiac Surgery, GSVM Medical College, Swaroop Nagar, Kanpur 208002 U.P (India)	Institutional Ethics Committee, GSVM Medical College, Swaroop Nagar, Kanpur-208002, U.P., India ECR/680/Inst/UP/2014/RR- 20	Dr. Santosh Kumar Sinha
9.	JIPMER, Dhanvanthri Nagar, Puducherry-605006	Institutional Ethics Committee, Research Division, 1st Floor, Administrative Block. Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER) ECR/342/Inst/PY/2013/RR-19	Dr. Santhosh Satheesh
10.	CARE Hospitals, Road No-1 Banjara Hills Hyderabad- 500034 Telangana, India	Institutional Ethics Committee, Road No-1 Banjara Hills Hyderabad- 500034 Telangana ECR/94/Inst/AP/2013/RR-21	Dr. B K Srinivasa Sastry

11.	JSS Hospital, Mahatma Gandhi Road, Mysore, 570004, Karnataka, India	Institutional Ethics Committee, JSS Medical College & JSS Hospital Sri Shivarathreeshwara Nagara, Mysuru (Mysore) Karnataka - 570015 India ECR/387/Inst/KA/2013/RR-22	Dr. Sunil Kumar S
12.	BP Poddar Hospital and Medical Research Ltd., 71/1, Humayun Kabir Sarani, Block G, New Alipore, Kolkata-700053, West Bengal	BP Poddar and Parvati Devi Foundation for Education 71/1, Humayun Kabir Sarani, Block G, New Alipore, Kolkata-700053, West Bengal. ECR/1812/Inst/WB/2023	Dr. SK Nasim
13.	Dept. Of Medicine, SMS Medical College & Attached Hospitals, J.L. N. Marg, Jaipur-302004, Rajasthan	The Institutional Ethics Committee SMS Medical College & attached Hospitals, Jaipur, The office of Ethics Committee, IInd Floor, Administrative Block, SMS Medical College, jaipur ECR/26/Inst/RJ/2013/RR-19	Dr. Puneet Saxena
14.	Noble Hospital Pvt. Ltd., 153, Magarpatta City Road, Hadapsar, Pune - 4111013	Noble Hospital Institutional Ethics Committee, Room No. 5, Clinical Research Department, Noble Annex, 153, Hadapsar, Pune – 411013 ECR/259/Inst/MH/2013/RR-19	Dr. Aparna N Kodre
15.	Shri BD Mehta Mahavir Heart Institute, Shree Mahavir Health Campus, Athwa gate, Ring road, OPD area, Surat - 395001, Gujarat	ShriBDMehtaMahavirHeartInstitute Ethics Committee Shri B D Mehta Mahavir Heart Institute Shree Mahavir Health Campus, Opp. Vanita Vishram Ground Athwagate, Ring Road Surat Surat Gujarat - 395001 India ECR/850/Inst/GJ/2016/RR-20	Dr. Atul Damodar Abhyankar

****